BiotechTube

BIIB074

Phase 2Terminated
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neuropathic Pain From Lumbosacral Radiculopathy

Conditions

Neuropathic Pain From Lumbosacral Radiculopathy

Trial Timeline

Feb 10, 2017 → Feb 7, 2019

NCT ID
NCT02957617

About BIIB074

BIIB074 is a phase 2 stage product being developed by Biogen for Neuropathic Pain From Lumbosacral Radiculopathy. The current trial status is terminated. This product is registered under clinical trial identifier NCT02957617. Target conditions include Neuropathic Pain From Lumbosacral Radiculopathy.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT02957617Phase 2Terminated
NCT02751905Phase 1Completed

Competing Products

20 competing products in Neuropathic Pain From Lumbosacral Radiculopathy

See all competitors
ProductCompanyStageHype Score
CHF6467 activeComac MedicalPhase 1/2
33
LY3857210 + PlaceboEli LillyPhase 2
52
OK-101 0.05% + OK-101 0.1% + PlaceboOKYO PharmaPhase 2
44
YHD1119 + LyricaYuhanPhase 3
77
YHD1119 300mg + YHD1119 300mgYuhanPhase 1
33
pregabalin sustained release tablet + pregabalin immediate release capsuleYuhanApproved
85
DS-5565 + placeboDaiichi SankyoPhase 3
77
Mirogabalin + PlaceboDaiichi SankyoPhase 3
77
DS-1971a + placebo + pregabalinDaiichi SankyoPhase 2
52
DS-5565Daiichi SankyoPhase 3
77
Placebo + MirogabalinDaiichi SankyoPhase 3
77
QutenzaAstellas PharmaPre-clinical
23
Qutenza exposureAstellas PharmaPre-clinical
23
Duloxetine + Pregabalin + PlaceboShionogiApproved
85
LY3016859 + PlaceboEli LillyPhase 2
52
LY3556050 + PlaceboEli LillyPhase 2
52
LY3526318 + PlaceboEli LillyPhase 2
52
LY4065967 + PlaceboEli LillyPhase 2
52
LY3848575 + PlaceboEli LillyPhase 2
52
ABT-639 + pregabalin + PlaceboAbbViePhase 2
52

Other Products from Biogen

Interferon-beta-1a + methylprednisoloneApproved
82
Dimethyl fumarateApproved
82
[18F]Florbetapir PET imagingApproved
82
dimethyl fumarateApproved
82
ibritumomab tiuxetan (Zevalin®)Approved
82